Complement dysregulation during the early phases of synucleinopathy
Acta Neuropathologica · 20.07.2026 · 152 (1)
DOI: 10.1007/s00401-026-03057-8 ↗Kurz gefasst
Fachartikel in der Zeitschrift Acta Neuropathologica, online erschienen am 20.07.2026. Verfasst von Hina Khan und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Translational Neuroscience, Michigan State University, Grand Rapids, MI, 49503, USA. Hauptthemen laut MEDLINE: alpha-Synuclein, Complement Activation, Synucleinopathies, Complement System Proteins. Die Arbeit nennt 94 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NINDS NIH HHS, NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
Parkinson’s disease (PD) is characterized by progressive degeneration of nigrostriatal dopamine neurons and synucleinopathy, which is the accumulation of aggregated α-synuclein (α-syn). Increasing evidence implicates α-syn-associated neuroinflammation as a contributor to PD pathogenesis, yet immune mechanisms linking synucleinopathy to neurodegeneration remain incompletely defined. Activation of the complement cascade occurs in PD and other synucleinopathies, but most studies report complement activation after overt neurodegeneration, making it difficult to conclude if complement is directly activated by pathological α-syn or secondarily following neurodegeneration. We used the rat α-syn preformed fibril (PFF) model, in vitro complement assays and postmortem human PD tissue to investigate whether pathological α-syn directly activates complement prior to overt neurodegeneration. The α-syn PFF model exhibits a protracted pathological time course and distinct temporal separation between peak α-syn aggregation and nigrostriatal degeneration. Thus, we quantified complement expression, activation, and regulation during the aggregation phase. Synucleinopathy caused complement activation prior to nigrostriatal degeneration, including upregulation of components of both the classical ( C1qa, C1r, C4b ) and alternative ( Cfd, Cfb ) pathways, the anaphylatoxin ( C3aR, C5aR ) and phagocytic ( CR3 ) complement receptors, and activation of complement C3. During early synucleinopathy microglia upregulated C3, which significantly correlated with synucleinopathy burden across several brain regions, including the substantia nigra pars compacta (SNc) and cortex. Concurrently, complement regulators, including Cd55, Cd59, neuronal pentraxin-1 (Nptx1), and the neuronal pentraxin receptor were downregulated in the synucleinopathy-affected SNc. Importantly, increased levels of C1q and iC3b along with downregulation of CD55 and NPTX1 protein were also observed in human postmortem PD SNc tissue, supporting the translational relevance of our findings. Mechanistically, we demonstrate that aggregated, but not monomeric, α-syn directly binds C1q and activates the complement cascade in a C1q-dependent manner. These data provide the first in vivo evidence that synucleinopathy triggers complement activation and dysregulation prior to neurodegeneration.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Translational Neuroscience, Michigan State University, Grand Rapids, MI, 49503, USA.
- Cell and Molecular Biology Program, Grand Valley State University, Allendale, MI, USA.
- Biomedical Sciences Program, Grand Valley State University, Allendale, MI, USA.
- Department of Pathology and Laboratory Medicine, Center for Neurodegenerative Disease Research, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.
- Department of Translational Neuroscience, Michigan State University, Grand Rapids, MI, 49503, USA. benskeym@msu.edu.
ORCID-Profile: Matthew J Benskey
Förderung
- NINDS NIH HHS
- NIH HHS
- National Institutes of Health
Zitieren
APA
Khan, H., Gifford, M., Kordbacheh, A., Bury, A., Panoushek, S., Cole-Strauss, A., Kemp, C. J., Luk, K. C., Steece-Collier, K., Kuhn, N. C., Kanaan, N. M., Sortwell, C. E., Patterson, J. R., & Benskey, M. J. (2026). Complement dysregulation during the early phases of synucleinopathy. Acta Neuropathologica, 152(1). https://doi.org/10.1007/s00401-026-03057-8
Vancouver
Khan H, Gifford M, Kordbacheh A, Bury A, Panoushek S, Cole-Strauss A, et al. Complement dysregulation during the early phases of synucleinopathy. Acta Neuropathologica. 2026;152(1). doi:10.1007/s00401-026-03057-8
BibTeX
@article{Khan2026,
author = {Khan, Hina and Gifford, Mary and Kordbacheh, Arash and Bury, Asher and Panoushek, Spencer and Cole-Strauss, Allyson and Kemp, Christopher J and Luk, Kelvin C and Steece-Collier, Kathy and Kuhn, Nathan C and Kanaan, Nicholas M and Sortwell, Caryl E and Patterson, Joseph R and Benskey, Matthew J},
title = {Complement dysregulation during the early phases of synucleinopathy},
journal = {Acta Neuropathologica},
year = {2026},
volume = {152},
number = {1},
doi = {10.1007/s00401-026-03057-8}
}
EUVIMED